George Soros's PTGX Position Overview
George Soros (via Soros Fund Management LLC) currently holds 100,000 shares of Protagonist Therapeutics, Inc. (PTGX) worth $8.73 M, representing 0.10% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, George Soros has initiated a new position in PTGX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
George Soros's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by George Soros
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +100,000 | New Buy | 100,000 | $87.34 |
George Soros's Protagonist Therapeutics Investment FAQs
George Soros first purchased Protagonist Therapeutics, Inc. (PTGX) in Q4 2025, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
George Soros has held Protagonist Therapeutics, Inc. (PTGX) for 1 quarters since Q4 2025.
George Soros's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q4 2025, adding 100,000 shares worth $8.73 M.
According to the latest 13F filing for Q4 2025, George Soros's firm, Soros Fund Management LLC, owns 100,000 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $8.73 M.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.10% of George Soros's publicly disclosed stock portfolio, making it one of their key holdings.
George Soros's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 100,000 shares, as reported at the end of Q4 2025.